Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
WARREN, N.J., March 28, 2016 -- MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm drug delivery technology to improve patient outcomes and address unmet needs, today provided an update on the development of PharmFilm Tadalafil for the treatment of erectile dysfunction. The Company has completed a pilot Pharmacokinetic (PK) study and, following a recent meeting with the U.S. Food and Drug Administration (FDA), plans on continuing its development efforts.
Tadalafil is a PDE5 inhibitor currently marketed in pill form for the treatment of erectile dysfunction and benign prostatic hyperplasia (BPH) under the brand name Cialis®, and for treatment of pulmonary arterial hypertension under the brand name Adcirca®. PharmFilm Tadalafil will be offered in single pack doses that can be carried easily without the necessity of a pill bottle. The product is discrete, portable, and can be taken with or without water.
“We are extremely pleased with the progress we have made in the development of PharmFilm Tadalafil,” said Keith Kendall, CEO of MonoSol Rx. “The success of our pilot PK study and positive outcome of our FDA meeting are important milestones in the development program, and we look forward to its further advancement.”
MonoSol Rx is currently exploring partnership opportunities for PharmFilm Tadalafil and has engaged ESC Advisors, a division of KEMA Partners LLC, to manage the partnering process.
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, and convenience of pharmaceutical and over-the counter products. MonoSol Rx 's leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com. More information about PharmFilm can be found at www.pharmfilm.com.
Contact MonoSol Rx Jessica Patel [email protected] The Ruth Group Lee Roth [email protected] (646) 536-7012
